HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Actinium Pharmaceuticals, Inc. (ATNM)
8.43  0.13  (1.57%) 01-20 00:59
Open: 8.47 High: 8.5
Pre.close: 8.3 Low: 8.1878
Volume: 435,208 Ave vol: 527,666
52w High: 19.47 52w Low: 4.710005
MA(50): 9.97 MA(200): 10.772
EPS: -2.144 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: https://www.actiniumpharma.com/
Market Cap (M): 115
Shares Out (M): 14
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.
Technical analysis
Overall: Outperform
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 12.03 Target 2: 13.90
Resist 1: 10.30 Resist 2: 11.90
Support 1: 7.70 Support 2: 6.41
Company key metrics
Revenue per Share: 0
Net Income per Share: -4.4012
Cash per Share: 1.8598
Book Value per Share: 1.1344
Price to Sales: 0
Price to Book Value: 6.77
Earnings Yield: -0.5731
Dividend Yield: 0
Debt to Equity: 1.0676
Debt to Assets: 0.5163
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.